All patients
Age < 65y (younger) Age > 65y Asian type cancer location (esophagus) cancer location (gastro-esophageal) cell type, adenocarcinoma cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male HER2 negative HER2 positive PD-L1 < 1% PD-L1 > 1% stage II stage III (locally advanced)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mEC - (neo)adjuvant (NA), nivolumab alone vs. placebo, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias events or deaths (EFS)detailed results CheckMate 577, 2021 0.63 [0.46; 0.86]
0.63 [0.46 ; 0.86 ] CheckMate 577, 2021 1 0% 794 NA not evaluable AE (any grade)detailed results CheckMate 577, 2021 1.81 [0.96; 3.41]
1.81 [0.96 ; 3.41 ] CheckMate 577, 2021 1 0% 794 NA not evaluable AE (grade 3-4)detailed results CheckMate 577, 2021 1.10 [0.80; 1.51]
1.10 [0.80 ; 1.51 ] CheckMate 577, 2021 1 0% 792 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 577, 2021 1.76 [1.04; 2.97]
1.76 [1.04 ; 2.97 ] CheckMate 577, 2021 1 0% 792 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 577, 2021 1.17 [0.64; 2.15]
1.17 [0.64 ; 2.15 ] CheckMate 577, 2021 1 0% 792 NA not evaluable SAE (any grade)detailed results CheckMate 577, 2021 0.99 [0.71; 1.36]
0.99 [0.71 ; 1.36 ] CheckMate 577, 2021 1 0% 792 NA not evaluable SAE (grade 3-4)detailed results CheckMate 577, 2021 0.98 [0.68; 1.42]
0.98 [0.68 ; 1.42 ] CheckMate 577, 2021 1 0% 792 NA not evaluable STRAE (any grade)detailed results CheckMate 577, 2021 2.94 [1.30; 6.65]
2.94 [1.30 ; 6.65 ] CheckMate 577, 2021 1 0% 792 NA not evaluable STRAE (grade 3-4)detailed results CheckMate 577, 2021 4.94 [1.49; 16.37]
4.94 [1.49 ; 16.37 ] CheckMate 577, 2021 1 0% 792 NA not evaluable TRAE (any grade)detailed results CheckMate 577, 2021 3.12 [1.46; 6.71]
3.12 [1.46 ; 6.71 ] CheckMate 577, 2021 1 0% 792 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 577, 2021 1.86 [0.80; 4.34]
1.86 [0.80 ; 4.34 ] CheckMate 577, 2021 1 0% 792 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 11:08 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 151
- treatments: 360,719,721,720